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Abstract: Chlamydia trachomatis remains an enigmatic bacterial pathogen with no vaccine 
yet available to treat human ocular and genital tract infections caused by tissue-tropic serovars 
of the organism. Globally, it is the leading cause of preventable blindness as well as the leading 
cause of bacterial sexually transmitted infections. The pathogen has a range of virulence factors 
that enable it to successfully evade both the innate and adaptive immune system of the host. 
The host immune system, although protective, paradoxically is also associated closely with the 
pathologies of trachoma and pelvic inflammatory disease – disease sequelae of some chlamydial 
infections and reinfections in some genetically susceptible hosts. In this review, we focus on 
what is known currently about the pathogenesis of ocular and genital infections caused by this 
mucosal pathogen. We also discuss novel insights into the pathogenesis of infections caused 
by the genital and ocular serovars of C. trachomatis, including a discussion of both pathogen 
and host factors, such as the human microbiota at these mucosal sites as well as the current 
immunological challenges facing vaccine development. Finally, we discuss the current progress 
toward development of a vaccine against C. trachomatis. A wide range of recombinant protein 
antigens are being identified and, hence, are available for vaccine trials. A plasmid-free live strain 
has recently been produced and evaluated in the mouse (Chlamydia muridarum) and monkey 
(C. trachomatis) models. The data for ocular infections in the monkey model was particularly 
encouraging, although the path to regulatory approval of a live vaccine is still uncertain. While 
still a major challenge, vaccines for ocular and genital C. trachomatis infections are looking 
more promising.
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Chlamydial epidemiology: global burden of disease 
Chlamydia trachomatis is an obligate intracellular bacterial pathogen primarily of 
human conjunctival and urogenital columnar epithelial cells.1,2 Infections of cells at 
these mucosal surfaces with tissue-tropic oculogenital serovars of C. trachomatis can 
result in trachoma (ocular serovars A, B, Ba, and C),3 the leading cause of infectious 
blindness, and can also result in the leading cause of bacterial sexually transmitted 
infection (STI) (genital serovars D–K, Da, Ia, and Ja).4 The STIs can lead to tubal 
infertility in infected, untreated (or treatment failure) women as a result of ascension 
of the bacteria into the endometrium and fallopian tubes.5 The global burden of these 
infectious diseases remains a significant public health problem as many primary 
infections remain undiagnosed and untreated due to the largely asymptomatic nature 
of each disease. It is estimated that 85% of women with STIs caused by C. trachomatis 
are asymptomatic.6 If left untreated, primary chlamydial infections may also persist 
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for years and cause disease sequelae in some infected hosts. 
Indeed, it is estimated that up to 40% of women with an 
untreated chlamydial genital tract infection develop pelvic 
inflammatory disease (PID) and also that one in four women 
with PID will develop infertility.7 Repeat detection of 
C. trachomatis commonly occurs in up to 20% of patients,8 
and if the same strain is detected by genotyping but not by 
culture, this may in fact represent a persistent, rather than a 
recurrent, infection.9
Globally, the World Health Organization (WHO) esti-
mates that annually over 105 million adults have newly 
acquired STIs caused by C. trachomatis.10 In the USA, 
between 2007 and 2012, the overall chlamydial  prevalence 
was 1.7%, suggesting that approximately 1.8 million 
 infections were nationally prevalent among sexually active 
females aged 14–39 years in this developed country. In 
those sexually active females aged 14–24 years,  chlamydial 
prevalence was reportedly 4.7% overall, with 13.5% 
 prevalence among non-Hispanic blacks.11 Notably, however, 
C. trachomatis STIs are much more important in develop-
ing countries, with estimates of 8.3 million new cases in the 
WHO African Region and 7.2 million new cases in the WHO 
South-East Asia Region.9
Trachoma is responsible for the global visual impairment 
of approximately 2.2 million people, 1.2 million of whom 
are irreversibly blind from the disease. Current reports are 
that 51 countries are known or suspected to be endemic 
for blinding trachoma, with an additional seven previously 
endemic countries (Gambia, Ghana, Iran, Morocco, 
Myanmar, Oman, and Vietnam) reporting that they have 
now achieved the outcome indicator target for “elimination 
of blinding trachoma as a public health problem”. Despite 
this encouraging outcome, the 2014 estimate for the global 
population at risk of trachoma is 232 million people.12
Chlamydial disease pathogenesis both for ocular and 
for genital infections is immune-mediated, with bacterial 
infections producing inflammatory reactions at both mucosal 
sites. The immune responses to chlamydial infections are 
partially protective; however, these local inflammatory 
reactions often result in asymptomatic infections that 
can covertly spread to cause tissue damage and scarring 
complications that can lead to blindness and infertility in a 
subset of those infected.
Public health programs currently are implemented world-
wide in attempts to control for both ocular and genital infec-
tions caused by C. trachomatis. The SAFE (Surgery, Antibiotic 
treatment, Facial cleanliness, and Environmental improve-
ments) strategy is recommended by the WHO for  trachoma 
control primarily to interrupt bacterial transmission.12 
Worldwide, by the end of 2013, 31 countries reported that 
they were actively implementing the SAFE strategy.13 In addi-
tion, national screening programs have been used in many 
countries for over 20 years along with early treatment inter-
ventions for controlling C. trachomatis STIs.14 However, both 
of these public health control programs, although effective 
at reducing active C. trachomatis infections and producing 
declined rates of disease sequelae, are also problematic. For 
the STI programs, there are two main problems: first, the 
greatest areas affected worldwide with these infections, ie, 
developing countries, have virtually no control programs in 
place; and second, it is hypothesized (the “arrested immunity” 
hypothesis15) that early antibiotic treatment interventions 
may in fact disrupt the acquisition of protective immunity in 
these populations. Trachoma elimination efforts also confront 
major obstacles for the successful implementation of the 
SAFE program due to conflict and insecurity in several areas 
of the 46 countries comprising the WHO African Region. 
A further problem is that the SAFE program involves mass 
antibiotic treatments of populations which in itself could 
potentially induce antibiotic resistance.
Obviously the current control programs for ocular and 
genital infections caused by C. trachomatis are suboptimal, 
with rising reinfection rates still occurring despite, or perhaps 
even attributed to, some aspects of these control efforts. Thus 
vaccines that are designed to prevent the acquisition and 
transmission of chlamydial ocular and genital infections, as 
well as to prevent the development of immunopathologies 
following these infections, clearly would be advantageous for 
controlling trachoma and STIs caused by C. trachomatis.
New insights into C. trachomatis 
pathogenesis
Infections of ocular and genital mucosae with the genetically 
similar serovars of C. trachomatis damage epithelial cells 
eliciting complex immune events to control disease outcome. 
However, chronic inflammatory responses involving 
both innate and adaptive immunity can have pathological 
consequences for the host with submucosal tissue remodeling 
and scarring of the conjunctival surface and fallopian tubes 
causing the symptomatic diseases of trachoma and PID in 
some patients.
Disease severity following chronic inflammatory 
responses to persistent or repeated reinfections is asso-
ciated with pathogen factors including virulence gene 
variants and the C. trachomatis plasmid.16,17 Infection sus-
ceptibility and disease pathogenesis is also associated with 
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a myriad of host factors including genetic polymorphisms 
and related immune responses.18,19 Changes in bacterial 
community structures and diversities at the ocular and genital 
mucosal sites are also important host factors that influence 
chlamydial disease outcomes. For example, it is becoming 
increasingly apparent that changes in the conjunctival and 
vaginal microbiomes of the host occur in trachomatous 
disease and also influence genital tract infections caused by 
C. trachomatis.20,21
Pathogen factors
Although the ocular and genital strains of C. trachomatis are 
strictly differentiated, with ocular strains lacking tryptophan 
synthase function,22 the genomes of C. trachomatis serovars 
are more than 99% identical,23,24 and the host–pathogen inter-
actions in chlamydial infections are known to be serovar- 
specific. A recent report from a Dutch STI clinic showed 
that in comparison with the other urogenital isolates, 
serovars D and E, two of the most prevalent urogenital 
serovars worldwide,25,26 induced the highest serological 
immunoglobulin G responses in women with urogenital 
C. trachomatis infections.27 In addition, it has also recently 
been shown that not only is the host–Chlamydia interaction 
serovar-specific, but that it is also able to induce different 
levels of immune responses in disparate host cells. When 
C. trachomatis serovars Ba and D infected monocytes and 
dendritic cells (DCs), lower levels of inflammatory cytokines 
were produced in the monocytes allowing the serovars to 
persist while higher cytokine levels were induced in the DCs 
causing degradation of serovars in these cells.28
Chlamydial plasmid
Important virulence factors of C. trachomatis that link to 
disease severity include the translocated actin-recruiting 
phosphoprotein (Tarp)29 and the Inc. proteins found on the 
surface of the parasitophorous compartments (inclusions) 
inside infected host cells.30 Another key C. trachomatis viru-
lence factor is the highly conserved 7.5 kB cryptic plasmid 
that regulates the transcription of chlamydial plasmid-
responsive chromosomal loci 31 and expression of pgp3,32 the 
plasmid gene encoding the virulence factor Pgp3.33
Studies using live attenuated chlamydial strains cured of 
the plasmid reveal that the plasmid contributes both to STI 
and to blinding trachoma pathogenesis. Genital tract infection 
of mice with the inflammation-inducing, plasmid-containing 
wild-type C. trachomatis Lymphogranuloma venereum 
(LGV) serovar L2 caused infertility in these animals, but 
infection with the non-inflammation-inducing, plasmid-free 
strain did not.34 The plasmid is also a crucial virulence factor 
in the nonhuman primate infection model of trachoma, 
where it has been shown that infections of macaque eyes 
with C. trachomatis organisms lacking the cryptic plasmid 
are highly attenuated and did not produce measurable ocular 
clinical pathology in these nonhuman primates,17 with recent 
confirmation that loss of pgp3 alone is enough to attenu-
ate the pathogenesis of acute chlamydial conjunctivitis in 
macaques.35 It is also known that the plasmid is not naturally 
transferred readily between clinical isolates supporting a 
host–plasmid tropism relationship.36 This has been confirmed 
by recent experiments aimed at developing a transformation 
system for non-LGV isolates of the ocular tropic C. tracho-
matis serovar A where it was observed that stable plasmid 
transformants were only obtained when the transforming 
plasmid shuttle vector was matched with the parental strain.37 
More recently, transcriptional profiling of cultured human 
epithelial cells infected with plasmid-deficient and -proficient 
C. trachomatis organisms has revealed statistically significant 
increases in the levels of expression of host genes coding 
for proinflammatory, immune suppression, and cell growth 
and fibrosis proteins in plasmid-bearing strains.38 This latter 
observation further supports the vital role that the chlamydial 
plasmid plays in immune avoidance and host cell inflam-
matory responses to C. trachomatis infections. Overall, it is 
interesting to note that the vast majority of C. trachomatis 
isolates have the plasmid. Naturally occurring plasmid-free 
strains are very rare. This confirms the central role that the 
plasmid has for chlamydial virulence and survival. While not 
proven, the plasmid products may also enhance transmissibil-
ity between hosts in some way.
Host factors
Host factors contributing to C. trachomatis disease severity 
include genetic variation in epithelial cells (eg, interferon [IFN] 
gamma receptors) and immune cells (eg, human leukocyte 
antigen [HLA] alleles on monocytes and interleukin [IL]-10 
promoter polymorphisms). Indeed, host polymorphisms in 
immune response genes – immunogenetic risk factors – are 
known to be significantly associated with susceptibility to, 
and severity of, C. trachomatis-induced inflammatory fibrotic 
diseases of trachoma and tubal factor infertility (TFI).16
In trachoma, several host inflammatory response genes 
have been identified as contributing to the severity of fibrotic 
disease leading to conjunctival scarring and trichiasis 
(turning-in of the eyelashes).39–41 For example, part of the 
host immune system’s initial defense against C. trachomatis 
infection is the activation and cytotoxic response of natural 
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killer (NK) cells which has been shown to be an important 
determinant of the severity of active trachoma.42,43 Recently, it 
has been reported that variants of the HLA gene C (HLA-C), 
in certain combinations with killer-cell immunoglobulin-
like receptor (KIR) genes (eg, the HLA-C2 homozygous 
KIR2DL2+, KIR2DL3+ genotype), are associated with a 
sixfold increase in the relative risk of scarring damage in 
trachoma, and these authors suggest a model of NK-mediated 
scarring in trachoma in which HLA-C2 genotype favors 
chronic infection while KIR2DL2/L3 heterozygosity favors 
chronic inflammation.44
Immunogenetic associations are also widely reported in 
many published studies for C. trachomatis-induced genital 
tract pathology such as TFI. These studies have investigated 
both immunological regulation of infection focused on genes 
that code cytokines and HLAs as well as genes related to 
fibrosis and tissue remodeling such as the matrix metal-
loproteinases (MMPs). The IL-12-related single nucleotide 
polymorphism IL12B 1188 A/C was reportedly associated 
with TFI and the severity of tubal damage in a study of 164 
TFI women with various degrees of tubal damage, 137 of 
whom had evidence of a past C. trachomatis infection.45 The 
chemokine CXCL13 (the ligand for CXCR5) was induced 
in fallopian tube tissue following C. trachomatis infection 
of the genital tract46 and the frequency of CXCR5 single 
nucleotide polymorphism +10950T.C (rs 3922) was found 
to decrease in women who developed tubal pathology after 
a C. trachomatis infection.47
In both ocular and sexually transmitted C. trachomatis 
infections, a specific genotype of the IL-10-coding IL10 
gene has been associated with disease. In scarring trachoma, 
the IL10-1082 GG genotype is associated with an increased 
risk of trachoma48 while the IL10-1082/-819/-592 GCC 
haplotype has been associated with a lower risk of recurrent 
infection in STIs.49 The tumor necrosis factor TNF-308A 
allele has also been associated with both ocular and genital 
C. trachomatis disease severity. This allele has been corre-
lated with increased TNF production and increased risk of 
pathological sequelae in trachoma40 and moderate-to-severe 
adhesions in TFI.44
Conjunctival and vaginal microbiomes
The human microbiome and particularly the diversity of 
commensal bacteria at healthy conjunctiva50 and vagina51 is 
increasingly being investigated for its impact on ocular and 
reproductive health in humans following infections with the 
tryptophan auxotroph C. trachomatis.
Of relevance to note here is that: 1) chlamydial growth and 
development in epithelial cells is inhibited by the cytokine 
IFN-γ that induces indoleamine-2,3-dioxygenase that can 
catabolize tryptophan52–55 and 2) genital (D–K), but not 
ocular (A–C), serovars have retained a functional tryptophan 
synthase that enables them to salvage any indole from their 
environment and synthesize tryptophan for growth.22 Also of 
note is that tryptophan deficit causes Chlamydia to enter the 
persistent (viable but non-cultivable56) growth form (reviewed 
in57). The ability of C. trachomatis to develop into a persistent 
form has been suggested as key pathogenetic mechanism 
underlying ocular and genital infections and the subsequent 
chronic disease sequelae of blinding trachoma, PID, ectopic 
pregnancy, and infertility. This is likely in part due to that 
fact that the persistent form of the organism can evade the 
host immune response and is more difficult to eliminate with 
antibiotics.58 Subfertile women with tubal pathology also have 
serological markers of persistent C. trachomatis infections 
and these markers are significantly more common when 
compared to women without tubal pathology.59
The abundance and composition of bacterial communities 
at the conjunctival site in healthy (or asymptomatic) humans 
have been characterized using 16S deep sequencing of the 
bacterial ribosomal gene in two studies. The first study 
was from four healthy American subjects and revealed two 
prominent non-indole-producing genera, Pseudomonas and 
Bradyrhizobium, in the ocular microbiomes of the 69.3% 
of sequence reads categorized to genus level, in addition 
to Propionibacterium and Corynebacterium.50 However, 
in contrast to these f indings, a more recent study of 
105 Gambian participants with normal healthy conjunctivae 
has reported six genera found in at least 80% of participants, 
and these included Corynebacterium, Streptococcus, 
Propionibacterium, Staphylococcus, Bacillus, and Ralstonia, 
with Corynebacterium and Streptococcus higher in 
115 participants with conjunctival scarring, and with 
Corynebacterium in even higher abundance in adults with 
clinical signs of scarring and trichiasis.20 Despite the fact 
that indole-producing Corynebacterium is a predominant 
component of healthy eyes, this genus has also been reported 
in trachomatous eyes,60 suggesting that changes in the 
normal conjunctival microbiome occur during trachomatous 
disease and also suggesting that non-chlamydial bacteria are 
associated with clinical signs of trachoma.20 Interestingly, 
genital tract serovars of C. trachomatis can also cause 
inclusion conjunctivitis, a sexually transmitted disease 
that generally follows autoinoculation from contaminated 
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genital secretions.61 Classically, chlamydial conjunctivitis 
initially affects one eye and this was reported in a recent 
case  study.62 It is therefore tempting to speculate that perhaps 
the indole produced by Corynebacterium is scavenged by the 
genital strains of C. trachomatis that are able to use indole for 
growth using the functional tryptophan synthase produced 
by these genital serovars.
In the vaginal microbiome of apparently healthy reproduc-
tive-age women, sequencing of ribosomal RNA genes revealed 
that non-indole-producing Lactobacillus species such as 
L. iners, L. crispatus, L. gasseri, and L. jensenii comprise 73% 
of the bacterial community while the remaining consisted of a 
large heterogeneous group of strictly anaerobic microorgan-
isms including Prevotella sp. that may express tryptophanase 
to produce indole.63 This latter bacterial community is the 
common and apparently normal vaginal community found in 
black and Hispanic women.51
Increased risks of acquiring and transmitting STIs such as 
HIV have been shown to be associated with decreased Lacto-
bacillus species in the vaginal microbiota.64–66 The interactions 
of vaginal microbiota and C. trachomatis were recently studied 
by analyzing the effects of Lactobacillus strains (L. brevis 
and L. salivarius) on the different phases of C. trachomatis 
developmental cycle. Lactobacilli had an adverse effect on 
chlamydial elementary bodies, on chlamydial adsorption to 
epithelial cells, and on intracellular phases of chlamydial 
replication. However, lactobacilli had protective effects toward 
persistent forms of C. trachomatis that were induced by HSV-2 
coinfection.67 The role of vaginal coinfections on human C. 
trachomatis genital tract infections has recently been reviewed 
with particularly focus on the suggestion that an altered vagi-
nal microbiome (as occurs in bacterial vaginosis) may provide 
a source of indole in vivo and that genital chlamydial strains 
can use indole to grow in this environment.21 Lactobacillus 
strains have also recently been reported to inactivate C. tra-
chomatis serovar L2 (the LGV pathogen) primarily through 
maintaining acidity by producing lactic acid and not through 
the production of hydrogen peroxide.68 Finally, it is also known 
that the vaginal microbiota is also impacted by sex hormones 
although the precise mechanisms of the estrogen/Lactobacil-
lus association are yet to be determined.69
These novel insights into the interactions of chlamydiae with 
their ocular and genital host cells, including host genetic poly-
morphisms and microbiota, need to figure prominently in the 
deliberations for designing vaccines to treat C. trachomatis infec-
tions (Figure 1) and are opined in the current literature.69,70
The need for chlamydial vaccines
Given the significant impact of C. trachomatis STI and dis-
ease worldwide, there continues to be major efforts to control 
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Figure 1 Summary of current challenges and progress in the development of a vaccine against C. trachomatis ocular and genital infections.
Abbreviations: C. trachomatis, Chlamydia trachomatis; GiT, gastrointestinal tract.
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it.71 These efforts can be divided into primary, secondary, and 
tertiary strategies. Primary prevention strategies traditionally 
have focused on education and changing people’s behavior 
and attitudes, and they have been successful in increasing 
condom use; however, they have had negligible impact on 
other sexual risk practices. Despite widespread knowledge to 
the contrary, recent data suggests an increase in the risk fac-
tors strongly associated with Chlamydia, such as having mul-
tiple sexual partners and overlapping partnerships.72,73 While 
education should continue to be a major control strategy, it 
is unlikely, on its own, to curb the increasing chlamydial STI 
rates. Secondary prevention involves screening, or at least 
testing, and then antibiotic treatment of infected individuals. 
Prevalence data from the UK and the USA, where over 25% 
of young women are screened annually, unfortunately does 
not show any reduction in prevalence of Chlamydia over 
time.10,74 It is not clear why there is no observed reduction 
in chlamydial STI rates, when mathematical models suggest 
that if 20% of women under 30 years of age are screened 
each year, the prevalence should be reduced by at least 
40%.75 One explanation may be the “arrested immunity” 
hypothesis,15 which suggests that early treatment actually 
prevents the development of any “natural” immunity, making 
these individuals as equally susceptible as naive individuals 
to subsequent chlamydial exposure.76 The other weakness 
of secondary prevention is the perceived effectiveness of 
the most commonly used antibiotic, azithromycin. While 
azithromycin is very effective in vitro, in practice, there are 
many more “treatment failures” than originally thought. 
Treatment failure rates range from 8% in women77 to 20% 
in men with “men who have sex with men” infections being 
particularly challenging.78
The reasons for treatment failure are several, including: 
1) true antibiotic resistance – unlikely; 2) failure of the individual 
to take the antibiotic – more likely for tetracyclines requiring 
multiple days of administration, but less likely for single-
dose azithromycin; 3) different mucosal absorption rates 
between individuals;79 and 4) heterotypic resistance in rela-
tion to populations of the organism. Tertiary prevention strat-
egies involve targeting the downstream pathology caused 
by C. trachomatis infections, such as PID,  infertility, and 
ectopic pregnancy. The issues here are that these pathologies 
are often: 1) asymptomatic, especially for women; 2) poorly 
diagnosed clinically; and 3) multifactorial.  Biomarkers that 
are predictive of disease are, therefore, urgently needed. For 
all of these reasons, a vaccine for genital tract infections 
caused by C. trachomatis is considered the only feasible 
solution.
The greatest demand for control of ocular chlamydial 
infections leading to trachoma is in the developing world.80 
While the SAFE strategy does work, the challenge is to 
deliver it to the poor regions where it is needed. If a vaccine 
was available for ocular C. trachomatis infections, then this 
could be utilized in conjunction with the SAFE program and 
elimination of trachoma may be one step closer.
The immunological challenges
Chlamydial immune responses can be 
partially protective but also can cause 
pathology
Protective immune responses to human ocular C. trachomatis 
infections are not well understood; however, what is known 
is that protective immunity does develop following natural 
infections and is associated with reduced incidence and 
duration of infections.81,82 Acquisition of natural immunity 
is also known to occur following human genital tract C. tra-
chomatis infections; however, the time to clear infection can 
take many months with a long-term follow-up study of the 
natural course of infection in asymptomatic women report-
ing that approximately 54% of the infections were cleared 
at 1-year follow-up.83,84 The risk for PID is also increased 
following additional exposures to human genital chlamydial 
infections.85 The immune responses to natural human ocular 
and genital tract infections with C. trachomatis thus provide 
incomplete protection and, in addition, are important in the 
development of tissue damage and the disease sequelae of 
blindness and TFI.
The pathogenesis and scarring caused by chlamydial 
infections has been proposed by Stephens as encompassing 
two paradigms: the cellular paradigm (epithelial cell layer is 
sufficient to explain pathology) and the immunological para-
digm (in which adaptive immunity explains pathology).86
innate immunity: protection  
and pathology
Protection from chlamydial ocular and genital infections 
involves both innate and adaptive immunity following 
the initial induction of proinflammatory and chemotactic 
cytokines such as IL-1α, IL-1β, IL-12, and granulocyte-
macrophage colony-stimulating factor from infected 
epithelial cells.87–89 A subsequent upregulation of these 
chemokines in Chlamydia-infected epithelial cells recruits 
innate immune cells to the infection site. For example, 
recruited to the site of infection following induction of 
CCL2 and CCL5 are macrophages and DCs; neutrophils 
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following chemokine (C-X-C motif) ligand 11 and CXCL8 
induction; and also NK cells following CXCL9, CXCL10, 
and CXCL16 induction.87,90 Immune-mediated control 
of chlamydial growth occurs through the contribution of 
TNF-α and IFN-γ that are released from these immune 
cells,91 noting that IL-12 levels were seen to be increased 
in the cervical monocytes from women infected with 
C. trachomatis.92 Innate immune pathways are also affected 
by female sex hormones with the genes for TNF-α, IL-17C, 
and type I and II IFN receptors (among other cytokine 
genes) upregulated in progesterone-treated endometrial 
cells that were infected with C. trachomatis.93 The roles 
of sex hormones in modulating immune responses in 
the female genital tract94 and particularly in relation to 
chlamydial infections95 have recently been reviewed.
Ocular pathology is related to the collateral tissue damage 
that occurs following cytokines triggering the initial immune 
response to chlamydial infections, and these cytokines are 
prominent both in active and in scarring trachoma.96 In 
children with active trachoma disease, an increase in the neu-
trophil chemotactic factor CXCL5 has been reported,97,98 and 
increased transcript levels of IL-1β have also been associated 
with chlamydial infection and active trachoma disease.99,100 
Conjunctival scarring was also found to be strongly associ-
ated with a proinflammatory, innate immune response and 
with increased expression of (among other factors) IL-1β, 
in a study of 363 trachoma cases. There was also differential 
expression of MMP-7, -9, -10, and -12 in trachomatis scar-
ring, although the expression of many of these genes was also 
significantly associated with the presence of non-chlamydial 
bacterial infection.42
An increasing number of studies indicate that innate 
immune responses to C. trachomatis infections arising from 
the epithelium and innate immune cells, along with changes 
in MMP activity, are likely to also be important in the 
development of genital tissue damage and oviduct fibrosis 
in TFI, with MMP-9 expression enhanced in response to 
chlamydial infections in vitro in human fallopian tube 
organ cultures101 and from neutrophils in vivo in a murine 
chlamydial genital tract model.102 Fallopian tube scarring 
associated with C. trachomatis genital tract infections may 
also be the result of increased production of inducible nitric 
oxide synthase, and mediators such as activins, that are 
secreted by infected tubal epithelial cells.103 Host factors 
associated with scar formation and other fibrotic conditions 
were also recently reported as being released from epithe-
lial cell monolayers as soon as 1 hour postinfection with 
C. trachomatis serovar E, and these findings have formed 
the basis of a hypothesis involving multiple feedback loops 
to explain Chlamydia-induced fibrotic scarring of fallopian 
tubes.104,105 These explanations for the pathology induced 
by chlamydial infections add to previous work showing an 
involvement of heat shock protein 60 and a proposed model 
of molecular mimicry which has been discussed extensively 
by Hafner.105
Adaptive immunity: protection and 
pathology
Cells of both the humoral (B-cells) and cell-mediated 
(T-cells) adaptive immune responses are also coordinated 
with cells of the innate immune response in attempts to 
protect against chlamydial infections.
Although chlamydiae are intracellular pathogens, and 
anti-chlamydial antibodies have a major role in protective 
immunity against chlamydial reinfections, there is increasing 
evidence that B-cells can protect against infectious agents 
using antibody-independent mechanisms.106
In trachoma, the protective role of antibodies remains 
to be elucidated, although it is known that the presence or 
absence of clinical signs of ocular disease is associated 
with specific antibodies directed against certain chlamydial 
antigens.107
In chlamydial infections of the murine genital tract, it 
has been reported that a deficiency in B-cells significantly 
reduced the endogenous Chlamydia-specific CD4+ T-cell 
responses within the local draining iliac lymph nodes and 
that infection was disseminated in these mice; thus, one 
possibility is that B-cells may also act as antigen-presenting 
cells during primary chlamydial infection and participate 
with the cell-mediated response in bacterial clearance to 
prevent chlamydial dissemination.108 Alternative possibili-
ties for the potential roles of B-cells in the draining lymph 
nodes during a primary Chlamydia genital tract infection 
have also been presented and include an effector function 
of B-cells to produce cytokines in response to microbial 
stimulation that may contribute to local defense in the 
lymph node.109 Interestingly, data from studies of autoim-
mune disease and allergic responses110,111 also suggest 
that B-cells can cause pathology by antibody-independent 
mechanisms, and since 1) the ascension of chlamydiae 
from the lower to the upper genital tract and, eventually, 
infection of oviduct epithelium are prerequisites for the 
development of long-term sequelae and 2) B-cells are 
involved in bacterial dissemination and cytokine produc-
tion, perhaps this is also the case for chlamydial-induced 
genital tract pathology.
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Acquired immunity and pathology
Although antibodies are involved in protection against 
infections caused by C. trachomatis,112 the most potent host 
defense mechanism is T-cell immunity, particularly involving 
the release of IFN-γ from host CD4+ and CD8+ T-cells.113–115 
It also known that IFN-γ-secreting CD4+ T-cells are required 
to home to the genital mucosa to drive T-cell-mediated pro-
tective immunity to chlamydial infections at this site,116 and 
that this is achieved by the adhesion receptor integrin α4β1 
in the murine genital tract.115
However, studies in humans have shown that the tissue 
damage and scarring sequelae of trachoma and TFI are the 
result of chronic, immunopathogenic responses to the chla-
mydial organism and are associated with T-helper (Th) cells 
such as Th1 and Th17.
In active trachoma, the expression of IL-17A, a proin-
flammatory cytokine (suggesting Th17 cell activity), is 
significantly increased,97 and IL-17A may contribute to 
fibrosis through epithelial–mesenchymal transition and 
increased collagen production.117 In scarring trachoma, there 
is also an increased expression of MMP-9 (gelatinase-B),42 a 
metalloproteinase that is induced not only by NK cells, but 
also induced and regulated by the Th1 cytokine, IFN-γ;118 
children with active trachoma also have increased amounts 
of conjunctival MMP-9.99
In the cervical cells collected from Chlamydia-infected 
women, the levels of IL-17 and IL-22 were significantly higher 
than the levels of these cytokines observed in noninfected 
women.119 It has also been reported that the levels of IFN-γ 
were significantly higher in the cervical washes of women 
with recurrent chlamydial infection, as compared to the 
cytokine levels from women with primary chlamydial genital 
infections.120 In a recent study of 250 women, 59 of whom 
had TFI, C. trachomatis-infected cells produced significantly 
higher levels of the IL-12B subunit, p40 than uninfected cells, 
providing evidence that genetic variation in the IL-12 cytokine 
family affects C. trachomatis-specific immune responses.121
Finally, as noted by Mabey et al, “an important difference 
between ocular and genital infection is that in the eye the dam-
aging sequelae occur at the site of infection, the conjunctival 
epithelium” while “by contrast in the female genital tract, 
the major sequelae develop in the fallopian tubes and not 
at the cervix, which is the site of inoculation”.80  Nevertheless, 
the pathology of C. trachomatis infection is similar in the 
eye and genital tract and involves a complex interaction 
of innate and adaptive immune responses to the organism 
that influence both protection and pathology in ocular and 
sexually transmitted chlamydial infections. Vaccine efforts 
against this intracellular pathogen will need to ensure that 
any immune responses generated by the ocular and genital 
vaccines will include the appropriate populations of innate, 
B, and T-cells that will engender protection and minimize 
pathology in the host.
Current progress toward the 
development of a vaccine
Natural infections can induce partial 
protection, but may also induce 
immunopathology under some 
circumstances
Studies in mice and humans (that have been approved by the 
relevant animal and human ethics committees) have provided 
results that support the fact that immunity can develop fol-
lowing natural, live chlamydial infections. In the well-studied 
Chlamydia muridarum-mouse model, it is well established 
that following a live intravaginal infection, immunity does 
develop, with immunized animals very strongly protected 
against a subsequent live chlamydial challenge dose.122 
Numerous experiments confirm the fact that major histocom-
patibility complex (MHC) class II-restricted CD4+ cells and 
IFN-γ are essential for this protection.122,123 Antibodies, par-
ticularly neutralizing antibodies, are suspected to play some 
role in the resolution of the primary infection but a much 
greater role in the resolution of secondary infections.124,125 
Animals that recover from an initial live chlamydial infec-
tion shed virtually no viable organisms upon challenge, a 
level of protection that, as yet, cannot be replicated using 
recombinant protein vaccines. However, along with protec-
tion against infection in these live infection studies comes 
severely increased immunopathology.126 A similar effect 
was observed in the early human trachoma vaccine trials 
in which inactivated whole chlamydial particles did confer 
some degree of protection, but unfortunately also led to a 
level of enhanced immunopathology in some vaccinated 
individuals.86,127 There is also good evidence in human genital 
tract infections that some women at least do develop a level 
of natural immunity,128 with this study showing that 18% of 
women attending sexually transmitted disease clinics for 
C. trachomatis infections naturally resolved their chlamydial 
infections prior to any antibiotic treatment. In a follow-up 
study, up to 22% of women spontaneously resolved their 
infections, and importantly, these women were significantly 
less likely to become reinfected, suggesting that their “natural 
immunity” not only helped them resolve their initial infec-
tion, but also protected them from subsequent infections.129 
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If we can define the basis of this human protection, while 
avoiding any adverse immunopathology, then a vaccine 
against C. trachomatis genital tract infections in women 
should be possible.
The choice of immunogenic target 
antigens is rapidly expanding
While early vaccine trials used whole, inactivated chla-
mydial particles, these will not be acceptable for vaccines 
as they contain the deleterious antigens that can lead to 
adverse immunopathology. As a consequence, efforts are 
now directed primarily toward defined recombinant proteins. 
While the chlamydial major outer membrane protein (MOMP) 
dominated early vaccine efforts, the good news is that the 
era of genome sequencing and reverse genetics has enabled 
a host of new chlamydial vaccine targets to be investigated. 
Not surprisingly, surface-exposed membrane proteins such as 
the MOMP, Omp2, and several Pmps, including PmpD and 
PmpG, are a major focus.130 However, a wide range of intra-
cellular proteins (NrdB, HtrA, GroEL, Nqr3, MAC–perforin, 
DnaK, IncA) as well as secreted proteins (Tarp, CPAF, CopB) 
are also showing promise.131–135 The strategies for identifying 
key antigens is also improving. The group of Brunham and 
colleagues used an immunoproteomic screening approach to 
identify antigens via their presented T-cell peptides in a C. 
muridarum-infected DC mouse model.136 Using this approach, 
they identified 13 Chlamydia peptides derived from eight 
novel epitopes presented by MHC class II molecules from 
bone marrow-derived DCs infected with Chlamydia. While 
some of the targets overlapped with previously identified 
targets (PmpG), others were novel (RplF, FabG, AasF, ClpP-1, 
Gap, PmpE). Other groups have used antigenic profiling of 
gene expression libraries to identify C. trachomatis proteins 
both with cell-mediated and with humoral immune responses 
in women with confirmed C. trachomatis genital tract 
infections, leading to several novel potential vaccine targets.137 
When they evaluated selected antigens in the urogenital C. 
trachomatis mouse model, perhaps not surprisingly, the bal-
ance between cell-mediated and humoral responses differed 
markedly between the different antigens.138
The rapidly expanding chlamydial genetic 
toolbox should expedite vaccine 
development
One aspect that has held the Chlamydia field back is the lack 
of a genetic transformation system and the ability to test gene 
mutants. This is one area that is rapidly changing and it should 
have a significant impact on vaccine  development. The chla-
mydial genetic transformation conundrum was cracked in 2011 
when the group of Clarke et al in Southampton, UK,139 showed 
that it was possible to develop a plasmid vector that contained 
both the chlamydial endogenous plasmid and an Escherichia 
coli origin of replication, so that it could shuttle between the 
two bacterial hosts. By paying careful attention to detail, the 
genetic transformation of several chlamydial species and strains 
has now become commonplace.140,141 An important addition 
around the same time was the use of chemical mutagens, such 
as ethyl methanesulfonate, to generate libraries of chlamyd-
ial mutants.142–144 Unfortunately, these mutants tend to have 
multiple mutations, but nevertheless, it is possible to screen 
such libraries to identify clones with your gene of interest 
disrupted, and subsequently to evaluate such mutants 
in vitro.144 By complementing the mutated gene with an intact 
gene on the plasmid shuttle vector, it is now possible to more 
definitively test the role of key virulence targets. Several of 
these newly characterized virulence targets are being evaluated 
as potential vaccine candidates.80 While the chlamydial genetic 
toolbox has expanded significantly over the past few years, it 
is likely to continue to become easier and easier to manipu-
late Chlamydia, with both forward and reverse genetics now 
being possible (eg, targetron approach), and more advanced 
techniques such as conditional gene silencing and transposon 
mutagenesis not far off.
is a live attenuated vaccine the answer?
For the past 10 years or so, virtually all efforts toward vaccine 
development have focused on the use of recombinant proteins 
either singly, or occasionally, as mixtures. Despite all efforts, 
the levels of “protection” obtained have usually been relatively 
modest. The general model used to evaluate vaccines has been 
the C. muridarum-mouse model, although continued excellent 
work is progressing using the guinea pig model.145–147 Protec-
tion is usually assessed following live genital tract challenge 
and is measured by any improvements in infection load (either 
peak of infection, total infection burden, or days to clearance) 
or reduction in pathology (physical size of the hydrosalpinx). 
By all measures, the candidate vaccines have not been able 
to produce a protective response anywhere near close to 
elimination of the organism, as can be seen following live 
infection. The effect on pathology reduction, by comparison, 
has been more impressive. The other major challenge is how 
the mouse model data will eventually translate into human 
studies. Caldwell et al17 at the Rocky Mountain Laboratories 
have attempted to overcome these issues by producing a 
live, attenuated (plasmid-free) strain of C. trachomatis and 
have evaluated its effectiveness in the monkey model. Their 
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results have been by far the most promising for future vaccine 
development. Kari et al produced a plasmid-deficient strain 
of C. trachomatis and used it to infect the eyes of cynomol-
gus macaque monkeys. They showed that, compared to the 
virulent wild-type strain, the attenuated plasmid-free strain 
resulted in short-lived infections that resolved spontaneously 
and, importantly, did not produce ocular pathology. They then 
challenged the vaccinated monkeys with the virulent wild-
type strain. All six unvaccinated animals developed severe 
pathology and extended infections. By comparison, three of 
the vaccinated animals were solidly protected, with virtually 
no infection and no adverse pathology. The other three vac-
cinated animals showed only partial protection, still having 
significant infections and pathology;17 thus, two major ques-
tions remain. First, will a similar protective effect be seen in 
humans and will it perhaps be HLA-restricted? Second, will 
it be possible to get approval from the authorities for a live, 
attenuated chlamydial vaccine?
Should we target gastrointestinal 
infections in addition to genital tract  
and ocular infections?
The final question relates to the site of infection. While 
there are similarities between ocular and urogenital sites of 
chlamydial infection, the strains of C. trachomatis that infect 
the sites are different (although there are only very minor 
genomic differences) and hence it is assumed that there will 
be two separate vaccines produced. One of the reasons is 
that the vaccines will most likely be used in very different 
settings, with the ocular trachoma vaccine being used in less-
developed countries where cost and distribution will be major 
issues, whereas the genital STI vaccine will be used in more 
affluent regions. In 2013 though, Yeruva et al reported that 
animals, and presumably humans, are commonly infected in 
the gastrointestinal tract with Chlamydia.148 These infections 
are generally chronic and exist for long periods of time 
without evidence of clinical disease. They also proposed that 
females, in particular, may be at risk of autoinoculation.149 
These findings suggest that for any chlamydial vaccine to be 
fully effective, it may make sense to target the chlamydial 
organisms present at all tissue sites, further challenging the 
type of immune response that is required.
Future directions
The pipeline for a protective and yet non-immunopathogenic 
vaccine against C. trachomatis ocular and genital tract 
infections is looking very promising. We now have a genetic 
toolbox to manipulate the obligate intracellular pathogen, 
and this augurs well for exciting rapid developments for a 
C. trachomatis vaccine. We continue to have an increased 
understanding of the potential vaccine targets that will best 
stimulate protective immunity against the pathogen while 
avoiding the deleterious adverse immunopathological reactions 
in the host. Microbiomes of the conjunctival and reproduc-
tive tracts are becoming increasingly well studied as are the 
effects of sex hormones estradiol and progesterone on genital 
and ocular microbiomes, chlamydial infections, and immune 
responses. The challenges that the organism presents to the host 
are becoming known, the host responses are being understood, 
and the progress toward a protective vaccine for C. trachomatis 
infections is occurring at an exponential rate.
Where to from here? The rapidly expanding genetic 
toolbox means that we should be able to understand and 
characterize more key chlamydial virulence factors. We 
should then be able to identify potential new vaccine targets 
that might enable improved levels of protection above those 
levels observed with the current vaccine targets. Live attenu-
ated vaccines are certainly one promising direction. Whether 
it is the plasmid-free strains or specific gene knockouts (not 
yet possible but perhaps not far off), the level of protection 
should be significantly better than what can be achieved using 
recombinant proteins. However, the key question is, will 
authorities ever approve a live, attenuated chlamydial vac-
cine? Will partial protection from a vaccine be sufficient to 
prevent disease sequelae? In fact, should at least some vaccine 
efforts be directed at vaccines that only target disease, rather 
than infection? Will the vaccine be able to be delivered to 
the disease endemic areas of the world? Yes, there are many 
questions, but with the rapid developments in our knowledge 
and technological expertise, we are well on the way to deliver 
protection without the paradoxical pathology of infections 
caused by the “cloaked” pathogen, ie, C. trachomatis.
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